Dexlansoprazole

Catalog No.S4099 Synonyms: T 168390, TAK 390

For research use only.

Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.

Dexlansoprazole Chemical Structure

CAS No. 138530-94-6

Selleck's Dexlansoprazole has been cited by 2 Publications

Purity & Quality Control

Choose Selective Proton Pump Inhibitors

Other Proton Pump Products

Biological Activity

Description Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.
Features A modified release formulation of an enantiomer of lansoprazole.
Targets
Proton pump [1] H(+),K(+)-ATPase [1]
In vitro

Dexlansoprazole, constitutes >80% of circulating drug after oral administration of lansoprazole, provides lower clearance and 5-fold greater systemic exposure than the S-enantiomer following oral administration of lansoprazole. Dexlansoprazole MR is a modified release formulation of dexlansoprazole, which employs a novel Dual Delayed Release (DDR) technology that delivers the drug in two discrete phases of release, thereby inhibiting newly activated proton pumps that turn over following initial PPI inactivation of H+,K+-ATPase. Dexlansoprazole MR maintains plasma drug concentrations above the threshold level longer than lansoprazole at all doses, resulting in an optimized drug exposure-intragastric pH relationship. [1] Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H+K+-ATPase proton pump in the gastric parietal cell, inhibition of this cell membrane enzyme ultimately blocks the final step in acid production. [2]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 369.36
Formula

C16H14F3N3O2S

CAS No. 138530-94-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02442752 Withdrawn Drug: Dexlansoprazole Pediatric Gastroesophageal Reflux Disease Takeda June 15 2025 Phase 1
NCT03316976 Completed Drug: Dexlansoprazole Healthy Volunteers Takeda November 22 2017 Phase 1
NCT03079050 Completed Drug: Dexlansoprazole 60 MG GERD|Proton Pump Inhibitor American University of Beirut Medical Center|Takeda February 27 2017 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dexlansoprazole | Dexlansoprazole supplier | purchase Dexlansoprazole | Dexlansoprazole cost | Dexlansoprazole manufacturer | order Dexlansoprazole | Dexlansoprazole distributor